RESUMO
PURPOSE: Erectile dysfunction (ED) is a worldwide health problem. Oral phosphodiesterase type 5 inhibitors (PDE5I) are used in its first-line treatment. This study aimed to compare the effects of hyperbaric oxygen (HBO) treatment with PDE5I treatment and determine the patient-dependent factors affecting the efficacy of the HBO treatment and duration of action of HBO treatment. METHODS: Adult male patients who presented to the HBO unit for HBO treatment with non-urological indications and had ED based on the International Index for Erectile Function (IIEF-5) constituted the target population of this study. Participants were given HBO treatment (Group 1), no treatment (Group 2), or daily oral tadalafil 5 mg treatment (Group 3). The treatment duration was 1 month. Patients were assessed by IIEF-5 both initially and after the completion of 1 month. RESULTS: There were significant increases in the mean IIEF-5 scores of the patients in Group 1 and Group 3 (p < 0.001, p < 0.001). However, there was no significant improvement in Group 2 (p = 0.496). Also, the post-treatment IIEF-5 scores of Group 1 and Group 3 were significantly higher than Group 2 (p < 0.001). There was no significant difference between the IIEF-5 scores and ∆IIEF-5 values of Group 1 and Group 3 (p = 0.166, p = 0.093). Evaluation regarding comorbidities revealed that patients with the peripheral vascular disease did not improve with HBO treatment (p = 0.285). CONCLUSION: HBO can improve erectile functions, and it can be a reasonable alternative for patients who cannot use PDE5Is due to comorbidities or treatment side effects.
Assuntos
Disfunção Erétil , Oxigenoterapia Hiperbárica , Adulto , Masculino , Humanos , Tadalafila , Disfunção Erétil/tratamento farmacológico , Estudos Prospectivos , Carbolinas/uso terapêutico , Inibidores da Fosfodiesterase 5 , Método Duplo-Cego , Resultado do TratamentoRESUMO
INTRODUCTION: To investigate whether combined treatment of hyperbaric oxygen (HBO) and core decompression (CD) result with better outcomes and have an additional influence on health quality scores when compared with HBO alone. METHODS: 63 consecutive patients' 80 hips (43 male, 20 female, 17 bilateral), diagnosed with Stage II Osteonecrosis of the femoral head were included in our study. The mean age at presentation in the HBO and CD + HBO groups were 39.9 years and 39.2 years, respectively. The mean follow-up was 39.8 months (24-56 months) for HBO group and 43.1 months (24-58 months) for the CD + HBO group. Standard radiographs and MRI were performed initially and during controls. Clinical outcomes were assessed using the modified Harris Hip Score (HHS), the visual analogue score (VAS) and SF-36 life quality score. RESULTS: 52 hips (65%) were Ficat Stage IIa and 28 hips (35%) were IIb. Totally, 46 hips (30 hips IIa, 16 hips IIb) were in HBO alone group and 34 hips (22 hips IIa, 12 hips IIb) were in CD + HBO group. Both VAS and HHSs were improved in each group after treatment (p < 0.001). When both groups were compared, this improvement was more distinct and evident in CD + HBO combination group than HBO alone group (p < 0.001). The physical function and pain components of SF-36 survey were found to be different in between two groups (p < 0.005). DISCUSSION: HBO treatment decreases pain, increases functional scores for Ficat Stage II patients. Addition of HBO treatment to decompression of the femoral head improves the results better than HBO alone. In particular, reduction of pain is more prevalent for Stage IIa patients than IIb with combination of HBO and CD therapies.
Assuntos
Artroplastia de Quadril , Necrose da Cabeça do Fêmur , Oxigenoterapia Hiperbárica , Humanos , Masculino , Feminino , Necrose da Cabeça do Fêmur/diagnóstico por imagem , Necrose da Cabeça do Fêmur/cirurgia , Descompressão Cirúrgica/métodos , Resultado do Tratamento , Dor/etiologia , Dor/cirurgia , SeguimentosRESUMO
OBJECTIVE: To evaluate the long-term results of using Memotherm (Angiomed Gmbh & Co.) prostatic stents in the treatment of bladder outlet obstruction from benign prostatic hyperplasia (BPH) in patients with high anesthetic risk for surgery. METHODS: A total of 29 patients with BPH, who were ruled unfit for surgery, underwent a prostatic stenting procedure between 1998 and 2005 at our hospital, with a mean age of 75 years (range, 65-87) and a mean symptomatic period of 62.5 months (range, 7-180). All patients had previous failed medical treatment for severe lower urinary tract symptoms and evaluated as high risk for anesthesia. Mean follow-up period was 6.8 years (range, 60-125 months). Preprocedural, first year, and fifth year postprocedural values for peak flow rates, residual urine volumes, Turkish symptom scores, and quality of life index scores were compared and evaluated. RESULTS: Memotherm prostatic stent placement was successful in treating 25 patients with BPH (86%) at high risk for surgery who had prostate-related urinary obstruction. For the remaining 4 patients (13.8%), stent migration into the bladder prompted removal of the stents. Marked improvement in residual urine volume, Turkish symptom score, quality of life index scores, and peak flow rates were observed 1 and 5 years after the procedure. CONCLUSION: The results of our study suggest that placement of Memotherm prostatic stents is an effective treatment option in elderly patients with BPH at high anesthetic risk. And by this way, the possible unwanted results of continuous catherization and patient discomfort might be prevented.